Panobinostat in Combination With Rituximab For Relapsed/Refractory Diffuse Large B Cell Lymphoma.

Trial Profile

Panobinostat in Combination With Rituximab For Relapsed/Refractory Diffuse Large B Cell Lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 May 2017

At a glance

  • Drugs Panobinostat (Primary) ; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jul 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Aug 2015, as reported by ClinicalTrials.gov.
    • 06 Aug 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 06 Jun 2011 Actual initiation date (Jun 2011) and lead trial investigators added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top